Multi-omics reveals the mechanism of vagus nerve stimulation in the treatment of chronic congestive heart failure
Rattachement africain : cn, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The potential benefits and underlying mechanisms of Vagus Nerve Stimulation (VNS) in the treatment of Chronic Congestive Heart Failure (CHF) remain insufficiently elucidated. Therefore, this study aims to investigate the therapeutic potential and mechanisms of VNS in treating CHF. In this study, models of CHF and VNS were established prior to performing echocardiography, H&E staining, and flow cytometry to evaluate the effects of VNS on pathological damage associated with CHF and myocardial mitochondrial dysfunction. Multi-omics analysis was conducted to identify changes in metabolites, gut microbiota, and gene expression following VNS treatment. Finally, QPCR was applied to measure levels of essential genes at the mRNA levels. VNS effectively enhances cardiac function, improves metabolic processes, and reduces inflammatory factor levels in dogs with CHF. VNS alleviates myocardial pathological damage, prevents the accumulation of ROS, and increases mitochondrial membrane potential. Multi-omics analysis identified five key metabolites, four key microorganisms, and sixty key genes. Furthermore, combined multi-omics analysis revealed key therapeutic targets, including three metabolites, four microorganisms, and sixteen genes. VNS significantly downregulates the mRNA expression levels of FSTL3, TNFRSF12A, and HBEGF. In summary, VNS has demonstrated effectiveness in the treatment of CHF. Key therapeutic targets identified include Kamahine C, FSTL3, TNFRSF12A, and HBEGF.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Multi-omics reveals the mechanism of vagus nerve stimulation in the treatment of chronic congestive heart failure
- Date Crossref
- 04/06/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.